Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits

Jayne Smith-Palmer1,*, Karin Cerri2 and William Valentine1

Abstract

Background: The goal of chronic hepatitis C treatment is to remove the virus to avoid progression of HCV-related disease. Sustained virologic response (SVR) is the most widely used efficacy endpoint in clinical studies of hepatitis C, and represents the eradication of HCV from the body. The aim of the current review was to examine the long-term clinical, economic and quality of life benefits associated with achieving SVR.

Methods: A systematic literature review was performed using the PubMed, EMBASE and Cochrane library databases to identify articles examining the clinical, economic and quality of life benefits associated with SVR, published in English language from 2002–2013. For inclusion studies were required to enroll ≥100 patients and to report clinical endpoints including hepatocellular carcinoma, overall- or liver-related mortality, or progression of disease/complications (e.g. portal hypertension, esophageal varices). Review of economic studies on cost/cost-effectiveness of achieving SVR were focused on studies assessing boceprevir/telaprevir plus pegIFN and ribavirin as this represents the current standard of care in several jurisdictions worldwide. Quality of life evidence was required to use validated quality of life instruments and provide a quantitative analysis of the impact of SVR versus no treatment or treatment failure.

Results: SVR is durable with late relapse rates over 4–5 year periods being in the range of 1–2%. Patients who achieve SVR frequently demonstrate some regression of fibrosis/cirrhosis and have a substantially reduced risk for hepatocellular carcinoma (relative risk [RR] 0.1–0.25), liver-related mortality (RR 0.03–0.2) and overall mortality (RR 0.1–0.3) in comparison with no treatment or treatment failure. In the 5 years post-treatment, medical costs for patients achieving SVR are 13-fold lower than patients not achieving SVR. Patients who achieve SVR also have health state utility values that are 0.05 to 0.31 higher than non-responders to treatment.

Conclusions: SVR represents the fundamental goal of antiviral treatment for patients infected with chronic HCV, so as to reduce risk of liver disease progression. Achievement of SVR has implications beyond those of clearing viral infection; it is associated with improved long-term clinical outcomes, economic benefits and improved health-related quality of life.

Keywords: Sustained virologic response, Chronic hepatitis C, Cost, Quality of life, Utility, Morbidity, Mortality

Background

On a global level over 2% of the population are estimated to be infected with the hepatitis C virus (HCV), which corresponds to a prevalent population of >180 million people with chronic infection [1]. For many patients who become chronically infected, HCV causes slow, progressive damage to the liver and represents one of the leading causes of cirrhosis and hepatocellular carcinoma (HCC) [2]. Moreover, the slow insidious nature of disease progression means that many patients are unaware of their status until the later stages of disease.

Six major genotypes of HCV exist in many regions and the current standard of care for patients with HCV genotype 1 is therapy with a direct acting antiviral (DAA) in combination with ribavirin alone or combined with pegIFN or a combination of two DAAs (with or without ribavirin). The present study focuses on HCV genotype 1
as this genotype occurs in all regions and is the predominant genotype in many regions.

The effectiveness of antiviral treatment, the extent to which treatment can clear viral infection is assessed according to the proportion of patients achieving sustained virologic response (SVR). SVR is the fundamental goal of treatment and is defined as undetectable (or below the lower limit of quantification) HCV RNA at 12–24 weeks after cessation of treatment [3,4]. SVR rates with a DAA in combination with pegIFN plus ribavirin (PR) currently range from approx. 80–90% for treatment-naïve patients [5-8], whilst SVR rates of up to 99% have been reported with combinations of two DAAAs [9]. Similarly, SVR rates of up to 99% have been reported in treatment-experienced (non-responders and relapsers) patients treated with two-DAA combinations [10].

Although considered a surrogate endpoint (a biomarker indicative of viral clearance rather than a finite endpoint such as presence/absence of disease or mortality), SVR is widely accepted as the best available indicator of viral clearance and a subject with SVR is generally considered cured [11]. Rates of late relapse are extremely low and long-term (up to 4 years) studies of patients treated with pegIFN have shown that SVR is durable, with approximately 99% of patients remaining virus-free, although the patient is still at risk of subsequent reinfection [12].

To date, the vast majority of clinical trials in HCV, including phase III trials of boceprevir and telaprevir, have used SVR at 24 weeks after the planned end of treatment (SVR24) as the primary endpoint. However, research in the field of HCV is currently advancing at a rapid pace and SVR 12 weeks after the end of treatment is now used as the primary endpoint in most clinical studies. The concordance between SVR12 and SVR24 rates has been investigated, and a high level of concordance was observed, suggesting that SVR12 represents a valid clinical endpoint [13,14]. Specifically, analysis was performed by the FDA in which data from fifteen Phase 2 and 3 trials (n = 12,000 patients) were combined to assess the concordance between SVR24 and SVR12. This analysis showed that concordance was observed between SVR12 and SVR24 for all treatments: 98% of patients with SVR212 had SVR24 [15].

As mentioned, SVR is the most commonly used endpoint in clinical trials in hepatitis C because the use of incidence of HCC or liver-related mortality as an endpoint is impractical within the context of a clinical trial. Patients with SVR following 24–48 weeks of treatment are generally considered to be permanently cured. While long-term follow-up is still required to fully assess the impact of SVR on hard clinical endpoints such as the progression to compensated or decompensated cirrhosis, HCC and liver-related mortality, it has been shown that patients who achieve SVR have a considerably reduced incidence of liver-related complications in comparison with those who fail treatment. As well as clinical implications, SVR rates can be anticipated to have an impact on the economic burden and humanistic burden of disease. HCV-related complications, such as HCC or liver-transplantation are associated with high direct medical costs and high levels of healthcare resource utilization [16], therefore any reduction in the incidence of HCV-related complications may have a considerable long-term economic benefit. This also extends to work productivity, as patients with SVR have higher post-treatment employment rates than those who fail treatment [17,18]. However, in the short-term improvements in SVR rates may be associated with increased pharmacy costs; for example, in an analysis in the French setting Deuffic-Burban et al. projected that the introduction of triple therapy would lead to a 3–4 fold increase in the number of genotype 1 patients receiving treatment at a cost of EUR 497–638 million [19]. As HCV is a transmissible disease, from a public health perspective, benefits of improved SVR rates include a reduced prevalent population and therefore the potential for lower transmission and incidence rates.

The objectives of the current study were to perform a literature review to understand the link between the clinical implications of achievement of SVR with the economic and patient quality of life implications by, firstly, exploring the clinical validity of SVR as an endpoint in terms of the impact of SVR on the incidence of liver-related complications including mortality and HCC and secondly, to assess the impact of attainment of SVR in terms of long-term economic outcomes and quality of life in patients infected with chronic HCV infection.

**Methods**

The search strategy for the literature review was designed using high level Medical Subject Heading (MeSH) terms and supplemented with free text terms and adapted for the PubMed, EMBASE and Cochrane Library databases as required; all initial searches were run on 08 January 2013 (subsequent searches with the same search terms were run on 29 April 2014 to capture studies published since the initial review was performed). For the PubMed searches, MeSH terms used included Hepatitis C [MeSH] OR Hepacivirus [MeSH]; free-text terms were used to identify articles focusing on sustained virologic response (wild-cards were used to capture variations in terminology). For the EMBASE searches, MeSH terms were mapped to EMBASE equivalents using the “map term” functionality.

The review was limited to articles published in the last 10 years and for inclusion, studies were required to be published in English and have a minimum enrollment of 100 patients (Table 1) (a minimum cohort size of 100 patients was chosen to focus on relatively large scale studies.
that could detect relatively small differences in outcomes and to preclude small scale pilot studies conducted in highly selective patient populations). The focus of the review was on patients with HCV genotype 1, and studies exclusively in patients with genotypes 2 and 3, or in patients with HIV coinfection, were excluded. Clinical studies were also required to have a minimum follow up of 1-year post-cession of treatment, compare outcomes in patients with SVR versus either untreated patients or those failing to achieve SVR, and report hard clinical endpoints; studies reporting biochemical parameters only, such as alanine amino transferase levels, were excluded. Cost-effectiveness studies were also limited to studies incorporating analyses of protease inhibitor-based triple therapy regimens; studies evaluating pegIFN plus ribavirin in comparison with pegIFN or IFN alone or no treatment were excluded. Studies reporting on health-related quality of life evidence were required to use validated quality of life instruments and provide a quantitative analysis of the impact of SVR versus no treatment or treatment failure.

The literature searches across the three databases identified a total of 4,206 unique hits after two rounds of screening (first round screening by title and abstract only and second round full-text screening of short-listed articles.) A total of 44 clinical studies (including 4 meta-analyses), 15 quality of life studies (one additional quality of life was identified in supplementary hand searches) and 2 economic studies were included in the final analysis (Figure 1). The review was performed in line with PRISMA guidance and a schematic diagram of the literature review process is shown in the Additional file 1. Updated searches performed in April 2014 identified an additional 20 clinical studies and 3 cost/cost-effectiveness studies.

### Table 1 Summary of inclusion and exclusion criteria applied in the literature review

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| All studies        | All studies       |
| Published 2003–2014| Conducted exclusively in HIV co-infected patients |
| Published in English| Conducted exclusively in pediatric patients |
| Conducted in patients with chronic HCV | Wrong publication type: letters, case studies, editorials and commentaries were excluded |
| Clinical studies   | Clinical studies |
| Minimum 1 year post-treatment follow-up | <100 patients |
| Report hard clinical endpoints (e.g. overall mortality, incidence of hepatocellular carcinoma) | Endpoints limited to biochemical parameters only (e.g. aminotransferase levels only) |
| Health economic studies | Health economic studies |
| Assessing cost-effectiveness of protease inhibitors versus pegIFN plus ribavirin, pegIFN, IFN or no treatment | Assessing pegIFN plus ribavirin versus pegIFN, IFN or no treatment |
| Quality of life studies | Quality of life studies |
| Presentation of quantitative results using a validated quality of life instrument | |

HCV, hepatitis C virus; HIV, human immunodeficiency virus; pegIFN, pegylated interferon; IFN, interferon.

### Results

#### Clinical benefits

The literature review process identified a large number of studies that examined the impact of SVR on the long-term risk of a number of clinical outcomes including incidence of HCC, liver transplantation, liver-related mortality and overall mortality in populations with differing levels of severity. Data were captured from a large range of patient populations in terms of relative prevalence of different HCV genotypes, severity of liver disease at baseline and treatment type.

#### Hepatocellular carcinoma

On a global level, HCV is one of the leading causes of HCC, and is typically associated with a poor prognosis. A total of 34 studies [20-48] including five meta-analyses [49-53] that examined the impact of SVR on risk of HCC were identified (Table 2). The overwhelming consensus of the results of the studies included was that patients who achieve SVR have a considerably reduced risk for HCC in comparison with untreated patients or those who fail to achieve SVR. However, the magnitude of this effect varied, with reported RRs for HCC in patients with SVR versus non-responders or untreated patients ranging from 0.09–0.35.

The 2010 meta-analysis by Singal et al. showed that patients who had SVR (following treatment with IFN alone or IFN plus ribavirin) had a RR (95% CI) for HCC of 0.35 (0.26–0.46) in comparison with non-responders [49]. Similarly, the meta-analysis by Kimer et al. reported a RR (95% CI) for HCC of 0.15 (0.05–0.45); however, the comparator group was untreated patients, rather than non-responders to therapy [51]. Notably, the analysis by Singal et al. included only studies in patients with...
cirrhosis, whereas the analysis by Kimer et al. included two studies in mixed or non-cirrhotic patients.

Studies examining the impact of SVR on risk for HCC in Japan are of particular interest owing to the high relative prevalence of HCV genotype 1b, (which is associated with a higher incidence of HCC than genotype 1a) and high incidence of HCV-associated HCC in this setting. For HCV patients with cirrhosis the annual probability of HCC is 1–4%, although this increases to 5–8% for patients with HCV genotype 1b [54,55]. Japan-based studies also showed that SVR was associated with reduced risk for HCC versus non-response, although as expected the absolute risk in both SVR and non-SVR population was increased with advanced age and increased severity of fibrosis. For example, Yoshida et al. determined SVR-related gain in HCC-free survival as both a function of age and fibrosis level (as measured by METAVIR F0–F4) [36]. For male patients with F0/F1 stage disease the gain in HCC-free survival with SVR was 2.48 years for patients aged 30 years, reducing to 0.15 years for patients aged 80 years. For patients with F4 stage disease SVR-induced gain in HCC free survival was 15.98 years at age 30 years, but only 2.38 years at age 80 years [36]. In another Japanese study by Imazeki et al., in the overall treated HCV population they report an annual HCC incidence of 0.5% for those with SVR versus 2.6%; whereas in patients with cirrhosis, the corresponding figures were 1.4% and 5.9%, respectively [46]. Similar findings were reported in other studies in the Japanese setting [22,24,29]. Only two studies (out of thirteen) from the Japanese setting reported no difference in the incidence of HCC for patients achieving SVR versus those without SVR [34].

Liver-related mortality
Analysis of clinical studies also showed that patients who achieve SVR have a substantially lower risk of liver-related mortality and overall mortality than non-responders to treatment, irrespective of genotype, setting or disease severity level, with a considerable proportion of studies showing that this reduction in risk was statistically significant (Table 3). In individual studies the RR for overall mortality for patients with SVR versus non-response or no treatment ranged from 0.14–0.70, whilst the corresponding figures for liver-related mortality were 0.03–0.22. As with HCC studies, the magnitude of the effect of SVR on mortality risk varied considerably between studies, which may be attributable in part to differences in patient characteristics such as mean age and disease stage prior to treatment. A 2010 meta-analysis reported a RR (95% CI) for liver-related mortality of 0.23 (0.10–0.52) for SVR patients compared with treatment failures, although if only patients with advanced fibrosis/cirrhosis were included this figure decreased to 0.13 (0.06–0.29) [50]. These findings were echoed in individual studies. For example, a
| Study | Setting | Sample size | Mean follow up | Study details | Key findings |
|-------|---------|-------------|----------------|---------------|--------------|
| Coverdale et al. 2004 | Australia | 455 | 9 years | Retrospective cohort study including 384 treated with IFN alone, (n = 71 untreated) including patients with cirrhosis | Overall 9-year incidence of HCC was 10% for untreated, 11% for non-response and 2% for SVR |
| Van der Meer et al. 2013 | Europe and Canada | 248 | 8.3 years | Cohort of consecutive genotype 1 patients with advanced fibrosis, 24% with SVR | HR (95% CI) for HCC for SVR versus non-SVR was 0.20 (0.06–0.69) (p = 0.011) |
| Van der Meer et al. 2012 | Canada | 530 | 8.4 years | Retrospective cohort study in patients with advanced fibrosis/cirrhosis treated with IFN, IFN plus ribavirin or pegIFN plus ribavirin, median follow up 8.4 years, 68% genotype 1 | Rate (per 100 patient years) for HCC were 0.55 (0.14–0.96) for SVR vs. 2.63 (1.83–3.82) without SVR (p < 0.001) |
| Braks et al. 2007 | France | 113 | 8.2 (3.1) years | Retrospective cohort study in patients with compensated cirrhosis treated with IFN or pegIFN-based treatment | Proportion of patients with HCC was 2.7% for SVR versus 31.6% for non-SVR |
| Cardoso et al. 2010 | France | 307 | 3.5 years | Retrospective analysis in patients with bridging fibrosis or cirrhosis treated with IFN, pegIFN or pegIFN plus ribavirin | Adjusted HR (95% CI) for non-SVR versus SVR was 3.06 (1.12–8.39) (p = 0.029) for HCC |
| Bruno et al. 2007 | Italy | 883 | 96.1 months | Retrospective database analysis in patients treated with IFN monotherapy with no cirrhosis or decompensation, 73.5% genotype 1 | Adjusted HR (95% CI) for non-SVR versus SVR was 2.59 (1.13–5.97) (p = 0.025) for HCC |
| Calvaruso et al. 2013 | Italy | 444 | 69 months (range 24–130 months) | Prospective cohort study in PR-treated patients with compensated cirrhosis, 83% genotype 1, 24% with SVR | HR (95% CI) for HCC for non-SVR versus SVR = 4.44 (1.30–15.11) (p = 0.017) |
| Pelliccelli et al. 2013 | Italy | 172 | 5 years | Retrospective-prospective study in patients with HCV genotype 1 treated with pegIFN plus ribavirin, 34% with cirrhosis | Multivariate OR (95% CI) for development of HCC for no SVR versus SVR = 3.58 (0.9–14.3) (p = 0.06) |
| Hara et al. 2014 | Japan | 1,125 | Not stated | Retrospective cohort study in PR-treated (SVR and non-SVR) and untreated patients | HR (95% CI) for HCC for SVR versus non-SVR and untreated = 0.12 (0.03–0.48) (p = 0.003) |
| Ikeda et al. 2006 | Japan | 2,166 | 15 years | Retrospective cohort study in patients with HCV patients (n = 512 untreated, n = 1,654 treated with IFN-based therapy) | Crude rate of HCC at 15 years was 13.9% for all treated patients, 23.9% for untreated and 7.5% for SVR |
| Imai et al. 2010 | Japan | 568 | 11 years | Retrospective cohort study in consecutive HCV patients treated with IFN monotherapy | HR (95% CI) for HCC for SVR versus non-treated patients was 0.20 (0.08–0.50) (p < 0.001) for patients <60 years and 0.23 (0.08–0.64) (p = 0.005) for patients >60 years |
| Imazeki et al. 2005 | Japan | 459 | 8.9 (3.2) years | Retrospective cohort study in patients, inc patients with cirrhosis, treated with IFN alone (n = 355) or untreated (n = 104), n = 116 patients achieved SVR | In the total population, annual incidence of HCC was 0.5% for SVR versus 2.6% for non-responders; corresponding figures for patients with cirrhosis were 9% and 34%, respectively |
| Kobayashi et al. 2007 | Japan | 1,124 | 66 months (range 12–197 months) | Retrospective cohort study in HCV patients treated with IFN or IFN plus ribavirin (373 with SVR, 751 without SVR) | HCC developed in 3.5% SVR patients versus 8.1% non-SVR patients. SVR HCC patients had a significantly more advanced stage of fibrosis (p < 0.001) |
| Maruoka et al. 2012 | Japan | 721 | 9.9 (5.3) years | Retrospective cohort study in patients treated with monotherapy (n = 577, of which n = 221 (38.3%) achieved SVR and n = 144 untreated patients | Annual rate of HCC development was 2.71% for untreated patients, 2.31% for non-SVR and 0.24% for SVR (p < 0.0001) |
| Moriyama et al. 2005 | Japan | 269 | >6 years | Retrospective study in patients with cirrhosis treated with IFN-based treatment | Mean annual incidence of HCC was 0.78% for SVR versus 0.17% for non-responders with ALT <80 IU and 4.68% for ALT >80 IU |
| Ogawa et al. 2013 | Japan | 1,013 | 3.6 years | Prospective multicenter study in patients treated with pegIFN plus ribavirin, 70.1% had HCV genotype 1 and 14.8% had cirrhosis at baseline | HR (95% CI) for HCC relative to SVR = 1.50 (0.65–3.44) (p = 0.34) for relapse and breakthrough and 3.72 (1.69–8.18) (p = 0.001) for non-response |
large scale (N = 1,215 treatment-naïve patients), UK-based retrospective study reported a multivariate HR (95% CI) for liver-related death for SVR patients of 0.22 (0.09–0.58) (p < 0.001) [56]. Similarly, an Italian study of HCV patients (with no cirrhosis) reported that not achieving SVR (versus SVR) increased the HR (95% CI) for liver-related death to 6.97 (1.70–28.42) [44]. Additionally, studies in the Japanese setting reported similar findings, with two studies reporting RRs for liver-related mortality of 0.03–0.04 for patients achieving SVR versus untreated patients [57,58].

The benefits of SVR in terms of reduced risk for liver-related mortality were apparent regardless of baseline severity. A multicenter study by van der Meer et al. [38] with over 8 years of follow up was conducted exclusively in patients with advanced fibrosis or cirrhosis at baseline.
| Study                        | Setting                  | Sample size | Mean follow up | Study details                                                                 | Outcomes assessed                                         | Key findings                                                                 |
|------------------------------|--------------------------|-------------|----------------|-------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------|
| Selzner et al. 2009 [59]     | Canada                   | 446         | 68 months<sup>a</sup> | Retrospective cohort study in liver transplant recipients treated with IFN-based therapy | Overall survival                                         | Actuarial 5-year survival rates were 96% for SVR and 69% for non-response (p < 0.0001) |
| Tanaka et al. 2013 [60]      | Canada                   | 245         | 5.7 years      | Retrospective single center study in liver transplant recipients undergoing treatment (agents not stated) | All cause mortality                                       | HR for all cause mortality for SVR versus non-response = 0.091 (0.04–0.21) (p < 0.001), HR for all cause mortality for relapse versus non-response = 0.19 (0.06–0.63) (p = 0.006) |
| Van der Meer et al. 2012 [38]| Europe and Canada        | 530         | 8.4 years      | Retrospective cohort study in patients with advanced fibrosis/cirrhosis treated with IFN, IFN plus ribavirin or pegIFN plus ribavirin, 68% genotype 1 | All cause mortality                                       | HR for all cause mortality for SVR versus non-SVR was 0.25–0.26 (p < 0.001) |
| Van der Meer et al. 2012 [61]| Europe and Canada        | 248         | 8.3 years<sup>a</sup> | Retrospective cohort study in patients with HCV genotype 1 with cirrhosis, treated with IFN-based treatment, 88% treatment-naive at baseline | All cause mortality                                       | Unadjusted HR (95% CI) for all cause mortality for SVR 0.20 (0.06–0.64) (p = 0.007) |
| Aguilera et al. 2012 [62]    | France                   | 114         | Not stated     | liver transplant recipients treated with pegIFN plus ribavirin                | Overall survival                                         | For patients with F0–F1, 10 year survival was 100% for SVR versus 76% for non-response (p = 0.024). For patients with F3–F4, 7-year survival was 85% for SVR versus 72% for non-response (p = ns) |
| Cardoso et al. 2010 [42]     | France                   | 307         | 3.5 years<sup>a</sup> | Retrospective analysis in patients with bridging fibrosis or cirrhosis treated with IFN, pegIFN or pegIFN plus ribavirin | Liver-related mortality                                  | Adjusted HR (95% CI) for non-SVR versus SVR was 3.71 (1.05–13.05) (p = 0.041) for liver-related mortality |
| Kutala et al. 2013 [63]      | France                   | 484         | 4.5 years<sup>a</sup> | Retrospective study in patients with advanced fibrosis, SVR rate was 30% in treated patients | All cause mortality                                       | 5 year survival rate was 100% in those with SVR vs. 54% for those without SVR (p < 0.0001), HR (95% CI) for mortality for non-SVR versus SVR was 6.8 (2.5–20.5) |
| Bruno et al. 2007 [44]       | Italy                    | 883         | 96.1 months    | Retrospective database analysis in patients treated with IFN monotherapy with no cirrhosis or decompensation, 73.5% genotype 1 | Liver-related mortality                                  | Adjusted HR (95% CI) for non-SVR versus SVR was 6.97 (1.70–28.42) (p = 0.0007) for liver-related mortality |
| Calvaruso et al. 2013 [23]   | Italy                    | 444         | 69 months<sup>a</sup> (range 24–130 months) | Prospective cohort study in PR-treated patients with compensated cirrhosis, 83% genotype 1, 24% with SVR | Liver-related mortality                                  | HR (95% CI) for liver related death for no SVR versus SVR = 6.56 (2.06–20.92) (p = 0.001) |
| Hara et al. 2014 [24]        | Japan                    | 1,125       | Not stated     | Retrospective cohort study in PR-treated (SVR and non-SVR) and untreated patients | All cause mortality                                       | HR (95% CI) for all cause mortality for SVR vs non-SVR and untreated = 0.08 (0.01–0.55) (p = 0.011) |
| Imazeki et al. 2003 [58]     | Japan                    | 459         | 8.2 (2.9) years| Retrospective cohort study in consecutive patients with CHC (335 treated with IFN and 104 untreated) | All-cause mortality, liver-related mortality              | Adjusted RR (95% CI) for all cause mortality for SVR versus untreated was 0.22 (0.07–0.71) (p = 0.0114), Adjusted RR (95% CI) for liver-related death was 0.03 (0.003–0.28) (p = 0.0017) |
| Study | Country | N   | Follow-up | Study Design | Endpoint(s) | RR (95% CI) for SVR vs. non-SVR = 0.47 (0.26–0.85) (p < 0.012) for non-SVR = 0.23 (0.08–0.66) (p = 0.007) | Notes |
|-------|---------|-----|-----------|----------------|-------------|-------------------------------------------------|-------|
| Kasahara et al. 2004 [57] | Japan | 2,954 | 6.0 (2.2) years | Retrospective cohort study in HCV patients with stage F0–F4 fibrosis, (n = 2,698 treated with IFN alone, n = 256 untreated) | All cause mortality, liver-related mortality | RR (95% CI) for all cause mortality versus untreated was 0.14 (0.08–0.23) (p < 0.001) for SVR and 0.78 (0.43–1.39) (p = 0.394) for non-response. RR (95% CI) for liver-related mortality versus no treatment was 0.04 (0.01–0.30) (p = 0.002) for SVR and 1.02 (0.54–1.90) (p = 0.962) |  |
| Maruoka et al. 2012 [40] | Japan | 721 | 9.9 (5.3) years | Retrospective cohort study in patients treated with monotherapy (n = 577, of which n = 221 (38.3%) achieved SVR and n = 144 untreated patients | Overall mortality, liver-related mortality | Annual liver-related mortality rate was 2.52% for untreated patients, 1.26% for non-SVR and 0.1% for SVR. Multivariate HR for all cause mortality versus untreated was 0.84 (0.50–1.42) for non-SVR and 0.17 (0.08–0.40) for SVR |  |
| Uenishi et al. 2008 [64] | Japan | 209 | 4.1 years | Retrospective cohort study in patients who underwent curative surgery for early stage HCC (n = 139 had no antiviral treatment, remainder treated with pegIFN plus ribavirin) | Tumor-free survival and recurrence of HCC | Tumor-free survival rate at 5 years was 54% for SVR group versus 23% for non-SVR/untreated group (p < 0.001) |  |
| Velosa et al. 2011 [39] | Portugal | 130 | 6.4 (4.0) years | Retrospective cohort study in patients with cirrhosis treated with IFN, IFN plus ribavirin or pegIFN plus ribavirin | Liver-related mortality | Liver-related mortality rate during follow up was 21% for non-SVR versus 0% for SVR |  |
| Aleman et al. 2013 [26] | Sweden | 351 | 5.3 years | Prospective multicenter study in patients with HCV-related cirrhosis treated with pegIFN plus ribavirin, 50% genotype 1 | All cause mortality, liver-related mortality | HR (95% CI) for liver-related mortality for SVR versus non-SVR = 0.18 (0.05–0.45) (p = 0.001) |  |
| Shih et al. 2012 [48] | Taiwan | 3,988 | 57.7 months | Retrospective analysis of patients with HCV monoinfection, (n = 344 patients treated with IFN-based treatment, n = 216 with SVR) | Liver-related mortality | Adjusted HR (95% CI) for SVR versus untreated was 0.19 (0.05–0.77) (p = 0.02) for liver-related mortality |  |
| Yu et al. 2006 [45] | Taiwan | 1,619 | 5.2 years | Prospective study in patients with or without cirrhosis (n = 562 untreated and n = 1,057 treated with IFN or IFN plus ribavirin) | Overall mortality | RR (95% CI) for overall mortality versus untreated control was 0.37 (0.14–0.99) (p = 0.047) for SVR and 1.32 (0.57–3.07) (p = 0.524) |  |
| Innes et al. 2012 [56] | United Kingdom | 1,215 | 5.3 years | Retrospective cohort study in previously naïve patients, 36% genotype 1, treated with IFN-based therapy, 14% patients with cirrhosis at baseline | Liver-related mortality | Adjusted HR (95% CI) for SVR versus non-SVR was 0.22 (0.09–0.58) for liver-related mortality (p < 0.01) |  |
| Backus et al. 2011 [65] | United States | 22,942 | 3.8 years | Retrospective database analysis in n = 12,166 genotype 1, n = 2,904 genotype 2, and 1,794 genotype 3 patients treated with pegIFN plus ribavirin | All cause mortality | Adjusted HR (95% CI) for all cause mortality for SVR versus non-SVR in HCV genotype 1 was 0.70 (0.59–0.83) (p < 0.0001) |  |
| Cozen et al. 2013 [66] | United States | 358 | 10 years | Retrospective database analysis in patients with HCV treated with IFN monotherapy or pegIFN plus ribavirin, 69% genotype 1 and 7.3% with cirrhosis at baseline | All cause mortality | HR (95% CI) for death or liver transplant vs. never treated patients = 0.23 (0.07–0.75) for SVR and 0.56 (0.24–1.32) for non-responder |  |
| Dieperink et al. 2014 [67] | United States | 536 | 7.5 years | Retrospective chart review of treated patients, 70% genotype 1, SVR rate of 41% | All cause mortality, liver-related mortality or transplant | HR (95% CI) for all cause mortality for SVR vs. non-SVR = 0.47 (0.26–0.85) (p < 0.012) |  |
Van der Meer showed that SVR led to a 3-fold reduction in the overall mortality rate (1.01 [0.46–1.56] per 100 patient years for SVR versus 2.93 [2.36–3.51] per 100 patient years for those without SVR; p < 0.001) and a 30-fold reduction in liver-related mortality or transplant (0.23 [0.01–0.50] per 100 patient years for SVR versus 3.20 [2.58–3.82] per 100 patient years for those without SVR; p < 0.001) [38].

Overall mortality
Achievement of SVR has also been shown to reduce the risk of overall mortality (Table 3). For example, in a US-based study, SVR was associated with a HR (95% CI) versus non-SVR for all-cause mortality (for genotype 1 only) was 0.70 (0.59–0.83) (p < 0.0001) [65]. Other studies report a much lower figure, with Morgan et al. reporting a HR (95% CI) for all-cause mortality or liver transplant of 0.17 (0.06–0.46) [41].

Other complications
Four studies identified in the review (conducted in Japan, Spain and the United States), showed that patients with SVR had a reduced risk for new onset diabetes in comparison with those not achieving SVR; in patients who achieved SVR the risk of developing diabetes was approximately 2-fold lower than for patients who failed treatment (Table 4). In all four studies investigating this associated the reduced risk for type 2 diabetes with SVR was statistically significant [69-72].

Economic implications
The incidence of late stage complications associated with HCV (e.g. HCC, decompensated cirrhosis and liver transplant) is a major contributor to the economic burden associated with HCV. In the US alone, direct annual costs associated with HCV exceed USD 1 billion [82], with annual per patient costs exceeding USD 50,000 for HCC and USD 110,000 for a single liver transplant [83]. Similarly, in Europe, a 5-country study by Vietri et al. showed that HCV patients have a high level of medical resource utilization leading to high direct costs as well as a high degree of absenteeism and presenteeism leading to high indirect costs. Indeed, Vietri et al. report direct annual costs of EUR 1,147 and indirect costs of EUR 7,533 per patient [84]. New antiviral treatment regimens that increase the SVR rate have the potential to influence future complication rates and therefore the overall economic burden; however, as triple therapy regimens are also associated with increased pharmacy costs in comparison with pegIFN plus ribavirin alone, cost-effectiveness analyses are required in order to quantify the estimated long-term clinical and economic benefits. The initial literature review and update captured a total of five studies that specifically assessed the economic benefits of treatment in terms of cost per SVR achieved or cost of SVR versus failure (Table 5) [85-89].

One 2013 US-based study Manos et al. examined follow-up costs for patients achieving SVR versus non-responders over a 5-year period [89]. They report that patients with SVR (all genotypes) have mean annual costs (2007 USD) of USD 6,301 versus USD 10,149 for non-SVR patients, with the difference attributed to higher hospital costs (USD 5,167 versus USD 2,641) and outpatient costs (USD 4,983 versus USD 3,661). A similar UK-based analysis reported that costs in the 5 years post-treatment were 13-fold higher for patients who failed treatment versus those who achieved SVR, which increased to 56-fold for patients who initially failed treatment and were then retreated [85].

Three cost-effectiveness analyses presented results in terms of cost or incremental cost per SVR achieved [86-88]. In an Italian-based analysis Camma et al. reported an incremental cost per SVR achieved (versus pegIFN plus ribavirin) of EUR 60,500 per SVR for boceprevir IL28B guided therapy and EUR 74,600 per SVR for telaprevir IL28B guided therapy (2011 EUR) for treatment-naïve patients with HCV genotype 1. However, a key limitation of this analysis is that US pharmacy costs were used as Italian costs were not available at the time of the analysis, which may have led to under- or over-estimation of the true cost-effectiveness [87]. Another analysis from the Greek setting showed that for the overall HCV genotype 1 population (including treatment naïve patients and prior non-responders and
| Study                      | Setting | Sample size | Mean follow-up | Study details                                                                 | Outcomes assessed                                                                 | Key findings                                                                                           |
|---------------------------|---------|-------------|----------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Coverdale et al. 2004 [47]| Australia | 455         | 9 years        | Retrospective cohort study including 384 treated with IFN alone, (n = 71 untreated) including patients with cirrhosis | Liver-related complications                                                              | Overall 9-year incidence liver-related complication rate was 29% for untreated, 25% for non-response and 2% for SVR |
| Abergel et al. 2004 [73]  | France  | 163         | Not stated     | Retrospective cohort study in patients with severe fibrosis treated with IFN alone (n = 64) or IFN plus ribavirin (n = 99) | Progression of fibrosis                                                                | Fibrosis progression rate decreased in both responders and non-responders to treatment. 33% SVR regressed from cirrhosis to severe fibrosis; corresponding figure for non-responders was 9% (p = 0.058) |
| Braks et al. 2007 [43]    | France  | 113         | 8.2 (3.1) years| Retrospective cohort study in patients with compensated cirrhosis treated with IFN, IFN plus ribavirin or pegIFN plus ribavirin | Liver-related complications                                                              | Proportion of patients with ascites was 5.4% for SVR vs. 10.5% for non-SVR, rates of digestive hemorrhage were 2.7% vs. 5.3%, respectively |
| Poynard et al. 2013 [74]  | France  | 933         | 6.3 years      | Prospective cohort study in HCV patients; 62% genotype 1                        | Regression of fibrosis, progression to cirrhosis                                       | HR (95% CI) for regression of fibrosis at 10 years for SVR versus non-response = 4.94 (2.59–9.44) (p < 0.001) HR (95% CI) for progression to cirrhosis = 0.185 (0.106–0.264) for SVR and 0.173 (0.123–0.224) |
| Roche et al. 2008 [75]    | France  | 113         | 31.4 months    | Open label study in with liver transplant recipients treated with IFN plus ribavirin or pegIFN plus ribavirin, 75% genotype 1 | Fibrosis stage                                                                        | For SVR mean (SD) necroinflammatory grade decreased from 1.9 (0.6) to 1.0 (0.6) post-therapy and improved in 71.5% and remained stable in 26% SVR patients; corresponding figures in non-SVR patients were 51.5% and 46%, respectively |
| Wiese et al. 2014 [76]    | Germany | 718         | 35 years       | Prospective, community-based multicenter study in women with HCV genotype 1, SVR rate of 46% in treated patients | Cirrhosis                                                                              | Incidence of cirrhosis at 35 years post-infection = 6.0% for SVR vs. 15.3% for non-SVR |
| Annicchiarico et al. 2012 [77] | Italy  | 135         | 44.4 months    | Prospective study in 135 HCV patients with cirrhosis                           | Portal hypertension                                                                    | Development of portal hypertension was 10% for SVR versus 40% for non-SVR (p < 0.0005) progression of portal hypertension was 25% for SVR vs. 48% for non-SVR (p < 0.01) |
| Bruno et al. 2010 [78]    | Italy  | 218         | 11.4 years     | Retrospective cohort study in patients with compensated cirrhosis (n = 149 patients treated with IFN or IFN plus ribavirin, but no esophageal varices | Esophageal varices                                                                      | Esophageal varices developed in 32% untreated patients, 39% non-SVR patients and 0% SVR patients |
| D’ambrosio et al. 2011 [79]| Italy  | 127         | 77 months      | Prospective cohort study in initially treatment-naive patients with compensated cirrhosis, treated with IFN plus ribavirin | Esophageal varices (development of and or progression in size/severity)                  | Development/progression occurred in 5% SVR patients versus 15% non-SVR patients. 8-year cumulative probability of esophageal varices was 6% for SVR vs. 30% for non-SVR (p = 0.03) |
| Arase et al. 2009 [69]    | Japan  | 2,842       | 6.4 years      | Retrospective cohort study in patients treated with IFN or pegIFN plus ribavirin, 6% patients had cirrhosis at baseline | Onset of type 2 diabetes                                                                | Adjusted HR (95% CI) for the development of diabetes for non-SVR vs. SVR was 2.73 (1.77–4.20) (p < 0.001) |
| Imazeki et al. 2005 [46]  | Japan  | 459         | 8.9 (3.2) years| Retrospective cohort study in patients, incl patients with cirrhosis, treated with IFN alone (n = 355) or untreated (n = 104), n = 116 patients achieved SVR  | Hepatic failure                                                                        | In the total population, annual incidence of hepatic failure was 0% for SVR and 0.5% for non-responders; corresponding figures for patients with cirrhosis were 0% and 1.0%, respectively |
scores than non-responder/relapser/untreated populations, both in terms of sub-domains and physical and mental component summary scores, with a large proportion of between group differences achieving statistical significance. On an individual domain level, in studies that used the SF-36, the largest differences between patients with SVR and those without were reported for general health followed by role physical [18,103].

Quality of life
The literature review process identified a total of 15 studies that examined HRQoL in patients with SVR [17,90–103], and a further study was identified via searches of the bibliographic sections of included studies [18]. The most commonly used instrument in HRQoL studies was the SF-36, and studies that used this almost universally showed that patients with SVR had better

### Table 4 Summary of clinical studies reporting the impact of SVR on liver-related complications (Continued)

| Study | Country | Sample | Median follow up | Type of study | Study population | Outcomes | Results |
|-------|---------|--------|------------------|---------------|-----------------|----------|---------|
| Uenishi et al. 2008 [64] | Japan | 209 | 4.1 years* | Retrospective cohort study in patients who underwent curative surgery for early stage HCC (n = 139 had no antiviral treatment, remainder treated with pegIFN plus ribavirin) | Tumor-free survival and recurrence of HCC | Tumor-free survival rate at 5 years was 54% for SVR group vs. 23% for non-SVR/untreated group (p < 0.001) |
| Lee et al. 2013 [80] | South Korea | 315 | 45 months* | Retrospective chart review, 86% patients treated, 15% with cirrhosis at baseline, SVR rate of 75% | Cirrhosis | Cumulative 5 year rate of cirrhosis was 27.6% for patients without SVR vs. 0% for patients with SVR (p < 0.01) |
| Canete et al. 2013 [81] | Spain | 105 | 9.3 years | Retrospective study of paired biopsy data in HCV patients with mild-moderate fibrosis treated with IFN plus ribavirin | Progression of fibrosis | Progression of fibrosis was reported in 5.3% patients with SVR and 50% patients with non-response (p < 0.0001). Fibrosis improved in 30.5% patients with SVR and 14.6% patients with non-response |
| Simo et al. 2006 [70] | Spain | 234 | 5.7 years | Retrospective cohort study in patients with HCV (without severe fibrosis) treated with IFN or IFN plus ribavirin, 79% genotype 1 | Onset of type 2 diabetes | HR (95% CI) for onset of diabetes for SVR vs. non-SVR was 0.48 (0.24–0.98) (p = 0.04) |
| Aleman et al. 2013 [26] | Sweden | 351 | 5.3 years | Prospective multicenter study in patients with HCV-related cirrhosis treated with pegIFN plus ribavirin, 50% genotype 1 | Decompensated cirrhosis (ascites, variceal bleeding, encephalopathy) | HR (95% CI) for hepatic decompensation for SVR vs. non-SVR was 0.23 (0.08–0.53) (p = 0.002) |
| Innes et al. 2012 [56] | United Kingdom | 1,215 | 5.3 years | Retrospective cohort study in previously naïve patients, 36% genotype 1, treated with IFN-based therapy, 14% patients with cirrhosis at baseline | Liver-related inpatient hospital episodes | Adjusted HRs (95% CI) for SVR versus non-SVR were 0.22 (0.15–0.34) for liver-related hospital episode (p < 0.01) |
| Cozen et al. 2013 [66] | United States | 358 | 10 years | Retrospective database analysis in patients with HCV treated with IFN monotherapy or pegIFN plus ribavirin, 60% genotype 1 and 7.3% with cirrhosis at baseline | Cirrhosis | HR (95% CI) for development of cirrhosis vs. never treated = 0.68 (0.26–1.80) for SVR and 2.35 (1.18–4.69) for non-responders |
| Hyder et al. 2013 [72] | United States | 20,486 | 5 years | Retrospective database analysis of US veterans with no history of diabetes treated between 1998–2007 | Onset of type 2 diabetes | HR (95% CI) for onset of type 2 diabetes for SVR versus non-response was 0.76 (0.70–0.82) (p < 0.0001) |
| Oni et al. 2011 [71] | United States | 8,687 | >6 years | Retrospective database analysis in patients treated with pegIFN-based treatment | Onset of type 2 diabetes | Rate of new onset of diabetes was 10.2% for SVR group vs. 15% for non-SVR group |

*Median follow up.
ALT, alanine aminotransferase; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; IFN, interferon; ns = not significant; SVR, sustained virologic response.

relapsers), that telaprevir-based triple therapy was dominant to pegIFN plus ribavirin in terms of cost per SVR gained (telaprevir was associated with a cost-saving of EUR 10,403 per SVR gained) [88].
| Study (setting) | Patients | Interventions | Key findings |
|----------------|----------|---------------|--------------|
| **Morais et al. 2013** (Brazil) [86] | Treatment-naïve patients with genotype 1 with F2 fibrosis in Brazil | Boceprevir plus PR and telaprevir plus PR | In the public health system cost per SVR was BRL 50,751 for telaprevir plus PR and BRL 63,481 for boceprevir plus PR. In the private health system cost per SVR was BRL 88,508 for telaprevir plus PR and BRL 82,518 for boceprevir plus PR |
| **Backx et al. 2014 (UK) [85]** | Treated genotype 1 patients | Patients treated with PR for a minimum of 2 months | For non-cirrhotic patients 5-year post-treatment costs were 13-fold higher for non-SVR patients vs. SVR (GBP 2,530 versus GBP 190), and 56-fold higher for non-SVR patients who were retreated (GBP 10,722) |
| **Camma et al. 2012 (Italy) [87]** | Treatment-naïve HCV genotype 1, aged 50 years with F2 fibrosis | Boceprevir- or telaprevir based triple therapy (including RGT) versus pegIFN plus ribavirin alone, time horizon of 20 years | ICER per SVR versus pegIFN plus ribavirin was EUR 56,960–85,650 for boceprevir and EUR 74,600–118,000 for telaprevir |
| **Yfantopoulos et al. 2012 (Greece) [88]** | Treatment-naïve and treatment-experienced HCV genotype 1 | Telaprevir-based triple therapy versus boceprevir-based triple therapy | In total population, mean cost per SVR was EUR 46,635 for telaprevir and EUR 56,146 for boceprevir. For treatment-naïve population cost per SVR was EUR 38,868 and EUR 42,983, respectively. For treatment-experienced patients cost per SVR was EUR 48,966 and EUR 59,902 respectively. Telaprevir was dominant to boceprevir |
| **Manos et al. 2013** (United States) [89] | Chronic HCV patients treated from 2002–2007, excluding pre- and post-liver transplant antiviral treatment | PegIFN plus ribavirin | In the 5 years following treatment mean yearly total (hospital and outpatient) costs in genotype 1 patients were USD 2,504 higher for non-responders than for patients with SVR (p = 0.042) |

HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; RGT, response-guided therapy; SVR, sustained virologic response.

| Method | Study | Value | Difference |
|--------|-------|-------|------------|
| EQ5D   | Thein et al. 2005 [93] | 0.83 | — | — |
|       | Chong et al. 2003 [95] | 0.83 | 0.76<sup>b</sup> | 0.07 |
|       | Van Rooijen et al. 2011 [99] | 0.84 | 0.70 | 0.14 |
| SF-36  | Thein et al. 2005 [93] | 0.74–0.90 | 0.70–0.86<sup>b</sup> | 0.04–0.05 |
| SF-6D  | Hsu et al. 2012 [103] | 0.71 | 0.66<sup>c</sup> | 0.05 |
|       | John-Baptiste et al. 2009 [18] | 0.71 | 0.65 | 0.06 |
| HUI3   | Thein et al. 2005 [93] | 0.77 | — | — |
|       | John-Baptiste et al. 2009 [18] | 0.70 | 0.58 | 0.12 |
|       | Hsu et al. 2012 [103] | 0.70 | 0.57<sup>c</sup> | 0.13 |
| HUI    | Chong et al. 2003 [95] | 0.77 | 0.73<sup>c</sup> | 0.04 |
| TTO    | John-Baptiste et al. 2009 [18] | 0.89 | 0.84 | 0.05 |
|       | Hsu et al. 2012 [103] | 0.88 | 0.80<sup>c</sup> | 0.08 |
| SG     | Thein et al. 2005 [93] | 0.86 | — | — |
|       | Chong et al. 2003 [95] | 0.86 | 0.79<sup>c</sup> | 0.08 |
| VAS    | Thein et al. 2005 [93] | 0.74 | — | — |
|       | Chong et al. 2003 [95] | 0.74 | 0.70<sup>c</sup> | 0.04 |
| Not stated | Liu et al. 2012 [104] | 0.933–1.00<sup>a</sup> | — | — |
|       | Chhatwal et al. 2013 [105] | 1.00 | — | — |

HUI3, Health Utilities Index Mark 3; SF-36, Medical Outcomes Study 36-item Short-Form Health Survey; SG, standard gamble; TTO, time trade off; VAS, visual analog scale.

<sup>a</sup>Age-specific quality of life weight.
<sup>b</sup>Untreated.
<sup>c</sup>Patients with mild/moderate HCV or chronic infection.
cost-effectiveness analysis by Liu et al. the mean utility value associated with SVR was dependent upon whether the subject had mild fibrosis or cirrhosis [104]. Previous studies have shown that HRQoL is influenced by disease severity, but the study by Liu et al. is one of the few studies to suggest the quality of life benefit of SVR is influenced by baseline disease severity. Utility values associated with the SVR state were strongly influenced by the method of assessment used and were typically highest using the TTO (ranging from 0.88–0.89) and standard gamble methods (0.86) (Table 6) and lowest using the SF-6D (0.71) and visual analog scale methods (0.74). Additionally, assessment of utility values using the EQ-5D valuation index led to values of 0.83–0.84 for SVR in comparison with 0.70–0.76 for non-response/relapse (Table 6) [95,99].

Most quality of life studies included in the review assessed HRQoL within the first year following treatment; however, two studies assessed the impact of SVR at >3 years after completion of antiviral therapy. Both Mauss et al. [17] and John-Baptiste et al. [18] reported that the HRQoL benefits of SVR persist over >3 years, with both studies showing that patients with SVR had significantly better scores in all eight domains of the SF-36 in comparison with those who had failed treatment. Both Mauss et al. [17] and John-Baptiste et al. [18] also showed that SVR was associated with long-term benefits in terms of work productivity. Mauss et al. reported that a significantly higher proportion of patients who achieved SVR were employed (56%) in comparison with non-SVR patients (41%; p < 0.0001) [17]. Similarly, John-Baptiste et al. reported employment figures of 67% for patients with SVR versus 51% for those who failed treatment (p = 0.02). This analysis also showed that long-term work and leisure capacity were significantly compromised in treatment failures in comparison with the SVR group. Treatment failures had a mean (SD) reduction in work capacity of 5.8 (18)%, versus 1.1 (6)% for SVR; the corresponding figures for reduction in leisure capacity were 10.7 (24)% and 3.3 (13%), respectively [18].

**Discussion**

The overarching aim of the present review was to consolidate published findings relating to the clinical, economic and quality of life benefits associated with achieving SVR and draw together these data to assess how clinical and quality of life benefits translate into economic benefits on both a per-patient and system-wide level. Previous research has largely focused on individual clinical, economic or quality of life aspects of SVR and has not examined how these benefits overlap and interact within a larger framework. For example, on an individual patient level, attainment of SVR is associated with lower risk of progression, HCC and liver-related mortality, less time spent in hospitals and improved symptoms and quality of life. However, when scaled up to a system wide level, SVR translates into substantial direct cost-savings for the payer due to costly complications avoided, as well as lower indirect costs due to lost productivity through absenteeism and presenteeism.

SVR is widely regarded as a cure and has been shown to be durable with rates of late relapse being in the region of 1–2%. In addition to halting progression of liver damage, SVR-induced regression of fibrosis and even cirrhosis has been reported. For example in a meta-analysis of 8 European studies, Veldt et al. reported regression of fibrosis in approximately one third of patients achieving SVR [106]. Additionally, risk factors such as heavy alcohol use or co-infection with hepatitis B may lead to progression of liver disease even in the presence of SVR. The clinical implications of potential low level viral persistence are not well characterized and it remains largely unknown whether it influences post-SVR progression of liver disease.

There is extensive evidence relating to the clinical benefits of SVR. A reduced risk for progression to cirrhosis, HCC, liver transplantation and liver-related mortality is evident regardless of setting, age, HCV subtype or level of fibrosis (Tables 2, 3, 4 and 7). However, the magnitude of the impact of SVR in terms of its impact on mortality rates varied notably between studies identified in this review, with some studies suggesting that following SVR the risk for liver-related mortality is comparable to that of the general population, whilst others suggest that mortality risk, although lower than for treatment failures, remains elevated in comparison with the general population. A contributing factor in this disparity may be heterogeneity in populations studied. Some studies excluded patients with advanced fibrosis or cirrhosis, whilst others were conducted exclusively in cirrhotic patients; there were also differences between patient populations in terms of age, previous treatment history, and the relative prevalence of different HCV genotypes.

The absolute risk and the magnitude of benefit does appear to be highly dependent on age and pre-treatment level of fibrosis. One study by Yoshida et al. [36] in the Japanese setting assessed the gain in HCC-free survival (defined as the difference in expected HCC-free survival with SVR versus without) according to age and fibrosis level. They report that the gain in HCC-free survival was greater when the subject was younger and had advanced fibrosis at baseline. For example for patients with stage F2 fibrosis the RR (95% CI) for HCC were 1.76 (0.47–6.67) for SVR versus 2.86 (1.59–5.13) for non-SVR, whereas for patients with F4 fibrosis the RRs (95% CI) increase to 4.78 (1.13–20.18) and 12.23 (6.81–21.95), respectively. A large proportion of the HCC studies identified in the current review (n = 11/24) were conducted in
The clinical benefits associated with SVR due to complications avoided translate into economic benefits from a third party perspective. The magnitude of economic benefit is difficult to quantify, due to uncertainty of prevalence estimates and continued advances in therapy leading to ongoing improvements in SVR rates but owing to the high cost, even a small reduction in the incidence of HCC would have considerable economic implications. In addition to direct costs, the attainment of SVR also translates into substantial savings for the payer. The risk of overall mortality is reduced by approximately 5-fold, and liver related mortality approximately 10-fold, versus non-SVR, although this is influenced by age and level of fibrosis prior to treatment.

Patients with HCV have been shown to be at elevated risk for co-morbid conditions including type 2 diabetes [110]. Three studies showed that patients with SVR had a lower incidence of new onset diabetes versus non-responders. The mechanism for this is not clear, although hypotheses include elevated insulin resistance caused by pro-inflammatory cytokines [71]. It is has also proposed that insulin resistance may influence the likelihood of achieving SVR, rather than SVR influencing diabetogenic processes [111]. HCV is associated with a number of other extra-hepatic complications, although there are a lack of data on the impact of SVR on these.

The clinical benefits of SVR are not limited to HCC. Patients with SVR have reduced risk of progression, liver transplantation and overall mortality in comparison with those not achieving SVR. Liver transplantation has a mean (global) cost of USD 146,960 in the year of transplant [16], so again even small reductions in the number of liver transplants required translate into substantial savings for the payer. The risk of overall mortality is reduced by approximately 5-fold, and liver-related mortality approximately 10-fold, versus non-SVR, although this is influenced by age and level of fibrosis prior to treatment.

Patients with HCV have been shown to be at elevated risk for co-morbid conditions including type 2 diabetes [110]. Three studies showed that patients with SVR had a lower incidence of new onset diabetes versus non-responders. The mechanism for this is not clear, although hypotheses include elevated insulin resistance caused by pro-inflammatory cytokines [71]. It is has also proposed that insulin resistance may influence the likelihood of achieving SVR, rather than SVR influencing diabetogenic processes [111]. HCV is associated with a number of other extra-hepatic complications, although there are a lack of data on the impact of SVR on these.

The clinical benefits of SVR are not limited to HCC. Patients with SVR have reduced risk of progression, liver transplantation and overall mortality in comparison with those not achieving SVR. Liver transplantation has a mean (global) cost of USD 146,960 in the year of transplant [16], so again even small reductions in the number of liver transplants required translate into substantial savings for the payer. The risk of overall mortality is reduced by approximately 5-fold, and liver-related mortality approximately 10-fold, versus non-SVR, although this is influenced by age and level of fibrosis prior to treatment.

Patients with HCV have been shown to be at elevated risk for co-morbid conditions including type 2 diabetes [110]. Three studies showed that patients with SVR had a lower incidence of new onset diabetes versus non-responders. The mechanism for this is not clear, although hypotheses include elevated insulin resistance caused by pro-inflammatory cytokines [71]. It is has also proposed that insulin resistance may influence the likelihood of achieving SVR, rather than SVR influencing diabetogenic processes [111]. HCV is associated with a number of other extra-hepatic complications, although there are a lack of data on the impact of SVR on these.

The clinical benefits associated with SVR due to complications avoided translate into economic benefits from a third party perspective. The magnitude of economic benefit is difficult to quantify, due to uncertainty of prevalence estimates and continued advances in therapy leading to ongoing improvements in SVR rates but owing to the high cost, even a small reduction in the incidence of HCC would have considerable economic implications. In addition to direct costs, the attainment of SVR also has implications on indirect costs such as lost productivity, with evidence to suggest that employment rates

| Study | Details | Outcomes assessed | Key findings |
|-------|---------|-------------------|--------------|
| Almasio et al. 2003 [107] | Systematic review and pooled analysis (N = 1,031 patients for cirrhosis analysis, N = 3,914 patients for HCC analysis) | HCC, progression to cirrhosis | Risk reduction for progression to cirrhosis for SVR versus no SVR = 0.22 (−0.36 to −0.08). Risk reduction for HCC = 0.09 (−0.13 to −0.07) |
| Kimer et al. 2012 [51] | Systematic review and meta-analysis of 8 RCTs and 5 prospective studies (N = 3,208 patients); random effects model used. Patients treated with IFN, pegIFN or PegIFN plus ribavirin | HCC | RR (95% CI for HCC for SVR versus no intervention = 0.15 (0.05–0.45) |
| Morgan et al. 2013 [53] | Systematic review and meta-analysis of 30 studies (N = 31,528 patients) (18 studies included in meta-analysis) investigating impact of treatment on risk for HCC | HCC | For patients at all stages of disease HR (95% CI) for HCC for SVR versus non-response = 0.24 (0.18–0.31) (p < 0.001) |
| Singal et al. 2010 [49] | Systematic review and meta-analysis of 20 studies (N = 4,700 patients) in treatment-naive patients treated with IFN or IFN plus ribavirin; random effects model used | HCC | RR (95% CI) for HCC for SVR versus non-responders = 0.35 (0.26–0.46) |
| Singal et al. 2010 [50] | Systematic review and meta-analysis of 26 studies (N = 13,191 patients) | HCC, hepatic decompensation, liver-related mortality | RR (95% CI) for SVR versus treatment failure were: HCC 0.21 (0.16–0.27) (p = ns) for all patients and 0.27 (0.19–0.39) (p = ns) for patients with cirrhosis. Liver-related mortality was 0.23 (0.10–0.52) (p = ns) for all patients and 0.13 (0.06–0.29) (p = ns) for patients with cirrhosis. RR (95% CI) Hepatic decompensation 0.16 (0.04–0.59) (p = ns) for all patients and 0.08 (0.03–0.21) (p = 0.02) for patients with cirrhosis |

CI, confidence interval; HCC, hepatocellular carcinoma; RCT, randomized controlled trial; RR, relative risk.
are higher amongst patients with SVR versus those without [17,18].

The clinical benefits associated with the achievement of SVR translate into clinically meaningful benefits for patients by improving symptoms, functioning and health related quality of life, compared with those not able to achieve SVR. The findings of quality of life studies consistently showed that patients with SVR had higher utility values and SF-36 and EQ-5D scores in comparison with those who did not respond to treatment. However, in the literature review it was noted that there is a paucity of quality of life studies with long-term follow-up (≥5 years). Although SVR leads to improved quality of life in the short-term, data relating to whether or not this improvement persists in the long term are lacking.

Although the scope of the present review was such that the endpoints of fatigue and depression were not assessed directly, SVR is also associated with other benefits in terms of patient reported outcomes including fatigue and depression, which are common side effects associated with antiviral treatment. The Fatigue Severity Scale (FSS) is a commonly used instrument to assess fatigue in HCV studies. The FSS has good reliability, validity and responsiveness and a total score ≥4 is indicative of severe fatigue. In addition to improved SVR, protease inhibitors are associated with benefits in terms of reduced fatigue. Published data relating to the magnitude of change in FSS score required to constitute a minimally important difference are lacking. However, analysis of phase III simprevir trial data indicate that a clinically meaningful change (improvement or worsening) may be as small as 0.33–0.34 and that patients with SVR have significant improvements in FSS score versus non-responders (Janssen, data on file).

The current study has several limitations that should be acknowledged with regard to interpretation of the findings. In particular, the review included studies that compare SVR groups with both untreated groups and non-ressper groups. Several studies in Japan have shown that risk of HCC and overall mortality are reduced, although not significantly in patients who receive treatment but fail to achieve SVR in comparison with untreated patients, although the mechanism behind this is poorly understood [57,112]. Moreover, in a considerable proportion of the studies reported here no distinction is made by the authors in the non-SVR groups in terms of null-response, partial response or relapse following treatment. The potential benefits of SVR in relapsers is an area that warrants further investigation as two studies included here suggested that patients who relapse have lower risks for overall mortality and HCC in comparison with true non-responders [37]. Similarly, whether benefits of SVR are different across different sub-populations, such as patients with hepatitis B or HIV coinfection, or is influenced by genotype, is an issue for future analysis. A further limitation of the current review is that no formal quality assessment of included studies was performed.

While this systematic literature review attempted to be as holistic as possible in capturing the impact of achieving SVR in patients chronically infected with hepatitis C, it was not possible to capture all possible consequences. For example, the benefits associated with reduced infection risk were not considered, and therefore represent a limitation of the review. Additionally, during the literature search it was noted that an aspect of HCV that is often overlooked in the literature is the stigma associated with HCV and the impact of this on patients’ quality of life, disclosure practices and treatment-seeking behavior. Stigma may be subtle and is inherently difficult to quantify. One of the key factors in stigma arises due to fear of transmission, which although limited to blood-borne routes, does not prevent stigma. Patients with SVR are no longer at risk of transmitting HCV to others, therefore the stigma associated with HCV should be removed. Another aspect to consider is the public health benefit associated with a lower population prevalence; a reduced population prevalence means that there are fewer people from whom HCV can be transmitted to others.

Conclusions
In conclusion, review of the literature has shown that achievement of SVR in patients with chronic HCV infection is associated with significant clinical, economic and quality of life benefits. Patients who achieve SVR, including those with advanced disease, have a substantially reduced risk of progression to cirrhosis, development of HCC and both liver-related and all cause mortality. This reduced risk of late stage complications also leads to economic benefits. Post-treatment, patients with SVR also have lower healthcare resource utilization versus non-responders, which also translates into substantial economic benefits from a healthcare payer perspective. Finally, the attainment of SVR is also associated with improved quality of life.

Additional file

Additional file 1: PRISMA Flow Diagram: Achieving sustained virologic response in hepatitis C: a review of the clinical, economic and quality of life benefits.

Competing interests
This manuscript was funded by Janssen Pharmaceutica NV. JSP and WW are current employees of Ossian Health Economics and Communications, which has received consulting fees from Janssen Pharmaceutica NV. KC is a current employee of Janssen Pharmaceutica NV.

Authors’ contributions
JSP performed data acquisition and analysis and prepared first and subsequent drafts of the manuscript. KC was involved in the conception and design of the review, contributed to first and subsequent drafts of the manuscript and was involved in the critical review of all drafts of the manuscript. WW contributed to data acquisition and analysis and was...
involved in the critical review of all drafts of the manuscript. All authors read and approved the final manuscript.

Grant support
This study was supported by funding from Janssen Pharmaceutica NV.

Author details
1 Ossian Health Economics and Communications, Ossian Health Economics and Communications GmbH, Baumleingasse 20, 4051 Basel, Switzerland.
2 Janssen Pharmaceutica NV, Beerze, Belgium.

Received: 19 August 2014 Accepted: 7 January 2015
Published online: 17 January 2015

References
1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wormser ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.
3. Jacobson IM, Poordad F, Brown Jr JS, Kwo PY, Reddy KR, Schiff E. Standardization of terminology of virological relapse in the treatment of chronic hepatitis C: panel recommendations. J Viral Hepat. 2012;19:236–43.
4. Wedemeyer H, Jensen DM, Godofsky E, Mari N, Pawlotsky JM, Miller V, et al. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology, 2012;56:2398–403.
5. Jacobson IM, Gore DJ, Foster GR, Fried MW, Reddy KR, Schiff E. Sofosbuvir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014; S0140-6736(14):60494–9.
6. Mann M, Marcellin P, Poordad F, de Araujo ES, Buti M, Hormans Y, et al. Sofosbuvir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;50:6736(14):60538–9.
7. Kowdle KV, Lavitz E, Crespo I, Hassanein T, Davis MN, De Micco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381:2100–7.
8. Lavitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.
9. Afzal N, Zeuzem S, Kwo P, Choikger M, Grillon N, Puoti M, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for previously untreated hepatitis C genotype 1 infection. N Engl J Med. 2014;366(13):1039–48.
10. Afzal N, Reddy KR, Nelson DR, Lavitz E, Gordon SC, Schiff E, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated hepatitis C genotype 1 infection. N Engl J Med. 2014;370:1889–98.
11. Pearlman BL, Trabu N, Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:880–900.
12. Swain MG, Lai MY, Shiffman ML, Cookley WG, Zeuzem S, Dieteck DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593–601.
13. Martinit-Perignon M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51:1122–6.
14. Campos-Varela I, Castells L, Esteban JI, Bes M, Rodriguez-Frias F, Sapsinchn G, et al. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients. Transplantation. 2010;89:1547–52.
15. Chen J, Florain J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144:1450–5.
16. El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ. 2012;15:887–96.
17. Mauss S, Petersen J, Witthoeft T, Busch HW, Christensen S, Zehnter E, et al. Sustained Responders have Lower Rates of Liver-Related Events and a Better Quality of Life and Productivity Compared with Non-Responders/Relapsers after Antiviral Treatment of Chronic Hepatitis C [abstract] Hepatology. 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2012 Boston, MA United States. 9–13 November 2012 pp 5.
18. John-Baptiste AA, Tonninsson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009;104:2439–48.
19. Deuffic-Burban S, Mathurin P, Pol S, Larsen C, Roudot-Thoraval F, Desenclos JC, et al. Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. Gut. 2012;61:290–6.
20. Van Der Meer AJP, Veldt BJ, Feld JJ, Wiedenreiter H, Dufour J-F, Lamert F, et al. Improvement of interferon-based therapy substantially reduced the number needed to treat to prevent HCC among HCV genotype 1 infected cirrhotics [abstract]. Amsterdam, Netherlands: 48th Annual Meeting of the European Association for the Study of the Liver, 2013.
21. Wang C-H, Chang K-K, Lin R-C, Kuo J-J. Insights into hepaticellular carcinoma occurrence and long-term outcomes in patients with chronic hepatitis C infection after successful antiviral treatment [abstract]. Singapore: 23rd Conference of the Asian Pacific Association for the Study of the Liver; 2013.
22. Sasaki R, Aibru S, Yamaski K, Komari A, Yatsushii H. Risk factors for hepatocellular carcinoma developed after sustained virological response in hepatitis C patients [abstract]. Brisbane, Australia: Abstract presented at the 23rd Conference of the Asian Pacific Association for the Study of the Liver; 2014.
23. Calvaruso V, BAVetta MG, Ferrari D, Grimaudo S, Conte E, Pipitone RM, et al. Risk of disease decompensation and HCC in patients with HCV cirrhosis non responders to Peg-IFN plus RBV [abstract]. Bologna, Italy; 19th National Congress of Digestive Diseases, Italian Federation of Societies of Digestive Diseases; 2013.
24. Hara T, Fukushima T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Sustained viral response reduces liver complications and total mortality among Japanese elderly with hepatitis C virus infection [abstract]. Brisbane, Australia: 23rd Conference of the Asian Pacific Association for the Study of the Liver; 2014.
25. Ogawa E, Furuyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol. 2015;58:495–501.
26. Almen S, Rahnborg N, Weland O, Daviddottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230–6.
27. Pellicelli AM, Vignally P, Romano M, Migliorelli L, Mazzoni E, Mecone F, et al. Impact of liver fibrosis in development of hepatocellular carcinoma in genotype 1 chronic hepatitis C patients treated with antiviral therapy: Long term follow up study [abstract]. 48th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2013 Amsterdam Netherlands. 24–28 April 2013.
28. Imai Y, Tamura S, Tanaka H, Hiramatsu K, Niyo S, Doi Y, et al. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat. 2010;17:185–91.
29. Kobayashi S, Takeda T, Enomoto M, Tamori A, Kavada N, Habu O, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007;27:186–91.
30. Moriayama M, Matsushita H, Aoki H, Shumizu T, Yamagami H, Shoda A, et al. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver Int. 2005;25:85–90.
51. Kimer N, Dahl AK, Gluud LL, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2012;2(5):1–7.

52. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:923–30.

53. Morgan JW, Baack B, Smith BD, Yartel A, Pitts M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.

54. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.

55. Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itok Y, et al. Management of hepatitis C. Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology. 2009. Hepatol Res. 2010;40:347–68.

56. Innes HA, Hutchinson SJ, Allen S, Bhattacharya D, Bramley P, Delahooke TE, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained virological response, and are discharged from care. Hepatology. 2011;54:1547–52.

57. Kudo H, Tanaka A, Okmura T, Imai Y, Tsuobuchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat. 2004;11:148–56.

58. Izakel F, Yokosuka O, Fujiki K, Saito H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology. 2003;38:493–502.

59. Selzner N, Renner EL, Selzner M, Aleyoi O, Kashti A, Therapondos G, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88:1214–21.

60. Tanaka T, Selzner N, Theraponsod G, Renner E, Lilly LB. Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. Transplantation. 2013;96:113–9.

61. Van Der Meer AJ, Veldt BJ, Feld D, Wedemeyer H, Dufour JF, Lammert F, et al. Sustained virological response improves overall survival in chronic hepatitis C patients with advanced fibrosis [abstract]. Hepatology. 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2012 Boston, MA–United States. 9–13 November 2012.

62. Aguilera V, Garcia M, Rubin A, Navarro L, Prieto M, Benenguer M. Improved outcome after anti-hcv therapy is less marked when therapy is started at advanced stages of fibrosis [abstract]. Journal of Hepatology. 47th Annual Meeting of the European Association for the Study of the Liver, Milan, Italy. 20–22 April 2012.

63. Kutala BK, Duval X, Guedj J, Asselah T, Marcellin P. Impact of antiviral therapy on survival in patients with advanced fibrosis – Experience of Beaujon Hospital 2000 to 2010 [abstract]. Amsterdam, Netherlands. 48th Annual Meeting of the European Association for the Study of the Liver, 2013.

64. Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol. 2008;98:358–62.

65. Backus LJ, Boothroyd DB, Phillips BR, Beloerio P, Halloran J, Mole LA. A sustained virological response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509–16.

66. Cozen ML, Ryan JC, Shen H, Lennig R, Yee RM, Sheen E, et al. Nonresponse to interferon-based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One. 2013;8:e51568.

67. Dieperink E, Pocha C, Thuss P, Krönt A, Colton S, Ho SB. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci. 2014;60:872–80.

68. Singal AG, Dharia TD, Malet PF, Alqahtani S, Pitts M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.

69. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.

70. Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itok Y, et al. Management of hepatitis C. Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology. 2009. Hepatol Res. 2010;40:347–68.

71. Simó R, Lecube A, Genesca J, Esteban JJ, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care. 2006;29:462–6.
71. Oni OA, Rao G, Pandya PK. Impact of sustained virologic response on incident diabetes in chronic hepatitis C [abstract]. Hepatology. 62nd Annual Meeting of the American Association for the Study of Liver Diseases. The Liver Meeting 2011 San Francisco, CA. United States. 4–8 November 2011

72. Hyder SM, Krishnan S, Promrat K. Sustained virologic response prevents the development of new type 2 diabetes in patients with chronic hepatitis C [abstract]. Gastroenterology. 2013;144(Suppl 1):S951. Conference: Digestive Disease Week 2013, DDW 2013 Orlando, FL. United States. 18–21 May 2013.

73. Abengel A, Darcha C, Chevallier M, Ughetto S, Henquell C, Pol S, et al. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol. 2004;16:219–27.

74. Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59:75–83.

75. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, et al. Hepatitis C virus infection in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14:1766–77.

76. Wiese M, Fischer J, Löbermann M, Göbel U, Grüngreiff K, Güthoff W, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology. 2014;59:49–57.

77. Annicchiarico BE, Siciliano M, Santonocito C, Zocco MA, Avolio AW, Barbaro F, et al. The role of fibrosis in the development of hepatocellular carcinoma in chronic hepatitis C. Liver Int. 2014;35(Suppl 2):484–91.

78. Bruno S, Crosignani A, Facchetti C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2013;55:2069–76.

79. D’Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell’Era A, Lampertico P, et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther. 2011;16:677–94.

80. Lee SJ, Yeon JE, Lee HJ, Yoon EL, Suh SJ, Kim JT, et al. Risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis C: long term outcome and prognostic factors [abstract]. Singapore: 23rd conference of the Asia Pacific Association for the Study of the Liver. 2013.

81. Canettz NJ, Gras-Moragues I, Giner I, Pajares-Rossello M, Cano JA, et al. Long-term evolution of liver fibrosis in mild-moderate chronic hepatitis C: Study with paired biopsies [abstract]. Journal of Hepatology. 48th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2013 Amsterdam Netherlands. 18–24 April 2013.

82. Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poodad F, Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int. 2010;30:1012–8.

83. McAdam-Marx C, McGarry L, Hane CA, Biskupiak J, Deniz B, Brihner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531–46.

84. Vietri J, Pragalaj G, El Khoury AC. The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries. BMC Gastroenterol. 2013;13:16.

85. Backx M, Leveszuk A, White JR, Cole J, Sreedharan A, van Sanden S, et al. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepat. 2014;21:208–15.

86. Morris AD, Pereira ML. Cost per cure of telaprevir and boceprevir in treatment-naive genotype 1 hepatitis c patients with F2 fibrosis in Conference.

87. Camma P, Petta S, Enea M, Bruno R, Bronte F, Capurso V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56:850–60.

88. Yfantopoulos J, Paparrini K, D’Angelo ER. A cost-effectiveness analysis of telaprevir versus boceprevir in the treatment of hepatitis C. A Greek national health system perspective [abstract]. Berlin Germany: ISPOR 15th Annual European Congress. 2012. p. A394.

89. Manos MM, Darbinoian J, Rubin J, Ray GT, Shvachko V, Denis B, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm. 2013;19:436–47.

90. Bini EJ, Mehandru S. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther. 2003;17:777–85.

91. Aroa S, O’Brien C, Zuevski S, Shifflin ML, Diago M, Tran A, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol. 2006;21:406–12.

92. Spigel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Hanful F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790–800.

93. Thein HH, Krah M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100:643–51.

94. Hassainie T, Cookley G, Sulkowski M, Smith C, Marines G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004;40:675–81.

95. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98:630–8.

96. Borkovsky HL, Snow KK, Malet PF, Back-Madura C, Fontana RJ, Sterling RK, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46:420–31.

97. Mathew A, Peiffer LP, Rhoades K, McGarity TJ. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha-2b and ribavirin. Health Qual Life Outcomes. 2006;4:30.

98. Hollander A, Foster GR, Weiland O. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol. 2006;41:577–85.

99. Van Rooijen EM, Hotho D, Aghroven M, Van Der Kolk A, Hansen BE, Knegt R, Uyl-De Groot CA. The cost and quality of life of hepatitis C in the Netherlands [abstract]. Value in Health. ISPOR 14th Annual European Congress Madrid Spain. 5–8 November 2011. pp A394-A395

100. Papastephanou V, Skorda L, Ligos P, Hietos M, Krikoulogi I, Zamani C, Karapanis S. Health-related quality of life in patients with chronic hepatitis C: The impact of antiviral therapy. European Journal of Internal Medicine. 10th Congress of the European Federation of Internal Medicine Athens Greece. 5–8 November 2011 pp S46

101. Björnsson E, Verbaan H, Oksanen A, Söderman J, Friberg S, et al. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol. 2009;44:878–87.

102. Younossi Z, Aggarwal J, Martin M, Hernandez N, Donepudi M, Bayliss M, et al. Health-related quality-of-life among genotype 1 treatment-naïve chronic Hepatitis C patients receiving telaprevir combination treatment: Post-hoc analyses of data from the advance trial [abstract]. Journal of Hepatology. 47th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2012 Barcelona Spain. 18–22 April 2012

103. Hsu PC, Federico CA, Kraiden M, Yoshida EM, Bremner KE, Anderson FH, et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol. 2012;27:149–57.

104. Liu S, Cipriano LE, Holodiny M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:79–90.

105. Chhatwal J, Ferrante SA, Brog C, El Khoury AC, Burroughs M, Bacon B, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value. 2013;16:973–86.

106. Veldt BJ, Saracco G, Boyer N, Cama C, Bellabuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004;53:1504–8.
107. Almasio PL, Venezia G, Craxì A. The impact of antiviral therapy on the course of chronic HCV infection. A systematic review. Panminerva Med. 2003;45:175–82.
108. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;50:1142–54.
109. Tanaka Y, Hanada K, Orto E, Akahane Y, Chayama K, Yoshizawa H, et al. Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatol. 2005;42:47–53.
110. Mehta SH, Biancati FL, Sulkowski MS, Strathdee SA, Szkllo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133(8):592–9.
111. Romero-Gómez M, Del Mar VM, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–41.
112. Shiratori Y, Ito Y, Yokosuka O, Imaekei F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105–14.